RGX-121 gene therapy for severe Mucopolysaccharidosis Type II (MPS II): Interim neurodevelopmental outcomes and biomarker results (4164)

Paul Harmatz, Maria L. Escolar, Roberto Giugliani, Yoonjin Cho, Dawn Phillips, Marie-Laure Névoret, Paulo Falabella

Neurology · 2021 · 11 citations · 0 references

Concepts

Abstract

To evaluate the safety and efficacy of CNS-administered gene therapy for severe MPS II